Welcome to our dedicated page for International Flavors&Fragranc news (Ticker: IFF), a resource for investors and traders seeking the latest updates and insights on International Flavors&Fragranc stock.
International Flavors & Fragrances Inc. (IFF) is a leading innovator in creating sensorial experiences that drive the world of flavors and fragrances. Headquartered in New York, the company partners with customers globally to develop unique products for the food, beverage, health, personal care, and household goods industries. With a strong commitment to discovery and innovation, IFF continuously explores new possibilities in both fine fragrances and beauty, as well as in beloved foods and beverages.
IFF's core businesses include the Nourish segment, which accounts for nearly half of its revenue. This segment specializes in producing flavors, texturants, and plant-based proteins, providing essential ingredients that enhance the appeal and functionality of food products. Additionally, the Health & Biosciences division, generating roughly one-fourth of the company's revenue, is renowned for its expertise in probiotics and enzymes, making significant contributions to health and wellness solutions.
The company leverages its global team of 7,300 professionals along with leading consumer insights, research and development, and creative expertise to deliver differentiated products. Their proprietary formulations and custom solutions are a testament to their innovative approach and customer-centric focus.
IFF has recently made remarkable advancements in excipient technology, presenting its comprehensive range at global events such as CPhI Japan 2024 and Vitafoods Europe 2024. These showcases highlight the company's commitment to driving pharmaceutical innovation, with notable products like METHOCEL™, ETHOCEL™, and POLYOX™ under its new controlled release platform, 'Timing is Everything'. This new platform emphasizes the importance of controlled release in pharmaceutical therapies, aiming to improve patient compliance and treatment efficacy.
IFF continues to expand its innovative offerings and partnerships, demonstrating a significant impact across various industries. The company's dedication to sustainability and precision in science and creativity positions it as a key player in transforming everyday experiences and contributing to a better world.
For more detailed information about their latest projects and developments, visit their official website at iff.com.
IFF (NYSE: IFF) has announced a $70 million expansion of its Cedar Rapids, Iowa facility, adding 47,000 square feet to produce high-quality fruit-based ingredients for the healthy snacks market. This expansion aims to create up to 40 new jobs and will be operational by the latter half of 2026. The facility will feature advanced technologies, high automation, and sustainable practices, including efficient heat recovery systems and minimized energy and water consumption.
The Cedar Rapids plant will be the first U.S. facility to produce TAURA by IFF ingredients, known for their clean-label fruit and vegetable pieces and pastes. These ingredients, already produced in Belgium and New Zealand, will enhance products like snacks, chocolates, cereals, and bakery items. The expansion will also improve supply chain efficiencies due to its proximity to U.S. customers.
Andy Muller, President of Food Ingredients, emphasized the competitive edge this expansion will provide in the healthy snacks sector, leveraging over three decades of proprietary technology. The existing Cedar Rapids plant, which currently produces enzymes for various industries, has seen substantial enhancements in recent years and employs over 200 workers.
IFF (NYSE: IFF) announced key changes to its executive leadership team. Simon Herriott, president of Health and Biosciences, will step down after 21 years of service. Leticia Gonçalves, former ADM's president of precision fermentation, will succeed him effective March 1.
The company also welcomed Andy Muller as president of Food Ingredients, who joined in December 2024 from Corbion. Yuvraj Arora has taken on the role of President, Taste and Chief Commercial Officer, while Ana Paula Mendonça (President, Scent) and Angela Strzelecki (President, Pharma Solutions) maintain their current positions.
These changes align with IFF's external reporting structure, reflecting the company's focus on strengthening its leadership across key divisions including Health & Biosciences, Food Ingredients, Taste, Scent, and Pharma Solutions.
IFF (NYSE: IFF) reported its Q4 and full year 2024 financial results, with full-year sales reaching $11.48 billion, flat compared to the previous year. On a comparable basis, currency neutral sales increased 6%, driven by double-digit performance in Scent and high-single digit growth in Health & Biosciences.
Full-year income before taxes was $278 million, with adjusted operating EBITDA of $2.21 billion. The company achieved earnings per share of $0.95, while adjusted EPS excluding amortization was $4.31. Cash flow from operations totaled $1,070 million.
For 2025, IFF expects sales between $10.6 billion to $10.9 billion and adjusted operating EBITDA of $2-2.15 billion. The guidance includes six months of Pharma Solutions results, assuming its divestiture closes on June 30, 2025. Comparable currency neutral sales growth is projected at 1-4%, with volume growth across all businesses.
IFF (NYSE: IFF) has launched its redesigned corporate website, www.iff.com, featuring significant improvements in scale, performance, and digital experience. The new site showcases IFF's leadership and portfolio value across its markets through improved navigation, fresh content, and enhanced lead-generation tools.
Key features include a comprehensive media center, an expanded sustainability hub, and sections dedicated to careers, history, insights, and science. The responsive design enables customized user journeys and better access to business-specific content. The revamp aims to increase brand recognition, strengthen customer relationships, and attract talent.
The website redesign reflects IFF's brand identity as a global leader in flavors, fragrances, food ingredients, health and biosciences, emphasizing the company's focus on delivering sustainable innovations through science, creativity, and heart.
IFF (NYSE: IFF) has launched ScentChat™, an AI-powered instant messaging application designed to revolutionize fragrance creation through real-time consumer feedback. The app integrates with popular messaging platforms like WhatsApp and Facebook Messenger, enabling direct communication between consumers and fragrance creators.
Using advanced semantic AI and Natural Language Processing (NLP), ScentChat™ analyzes consumer feedback and generates instant insight reports that help perfumers make informed decisions about ingredients. The tool addresses traditional barriers in consumer research by offering a cost-effective, accessible, and scalable solution for gathering authentic sensory feedback.
The application represents a significant advancement in applying generative AI to perfumery, combining human experience with technology to streamline the fragrance creation process. It creates a collaborative environment between consumers and creators while making innovation more efficient and impactful.
IFF (NYSE:IFF) has announced its schedule for upcoming investor events in February 2025. The company will release its fourth quarter and full year 2024 earnings results after market close on February 18, 2025. A live webcast with management to discuss results and outlook will follow on February 19, 2025, at 9:00 a.m. ET.
Additionally, IFF management will present at the Consumer Analyst Group of New York (CAGNY) conference on February 20, 2025, at 1:00 PM ET. Both events will be accessible through webcasts on the company's investor relations website at ir.iff.com, with replay options available for those unable to attend live.
IFF (NYSE:IFF) has launched Enviva® DUO, a new direct-fed microbial (DFM) solution for poultry production. The product features a blend of two non-spore forming bacterial strains designed to support beneficial gut bacteria growth and promote optimal bird performance through waterline application.
The solution targets specific houses or farms through direct dosing, ensuring challenged birds receive microbiome-boosting benefits even during decreased feed intake. Scientific research validates Enviva® DUO's ability to restore bird microbiome and stabilize intestinal environment, while its stable formulation ensures uniform distribution without settling in water systems.
The product is currently available in the U.S., India, and Pakistan, with planned expansion to other markets pending regulatory approvals.
IFF Pharma Solutions has been awarded the 2024 Pharmaceutical Technology Excellence Award in the Brand Leadership category for its 'Timing is Everything' campaign. The campaign showcases IFF's new controlled release platform for oral drug delivery, implementing a three-pronged approach including social media teasers, video content, and a microsite.
The platform features key products including METHOCEL™, ETHOCEL™, and POLYOX™, focusing on controlled release polymers in pharmaceutical formulations. The campaign creates a comprehensive thought leadership platform providing educational resources such as white papers, webinars, and articles about controlled release of active ingredients.
The Pharmaceutical Technology Excellence Awards, powered by GlobalData's business intelligence, recognizes significant achievements and innovations in the pharmaceutical industry. The award acknowledges the campaign's strategic marketing tactics, creativity, and leadership in building an integrated thought leadership platform.
IFF (NYSE: IFF) has launched the China Scent Exploration Program, a consumer learning initiative aimed at creating unique fragrances for the Chinese market. This program leverages IFF's long-standing regional expertise, which began in 1981, and combines artificial intelligence with deep cultural insights.
According to Ana Paula Mendonça, President of Scent at IFF, the Chinese fragrance market offers significant opportunities. The program targets a market that includes fine fragrance ($2.15 billion), beauty and personal care ($77.35 billion), and home care ($18 billion).
The program is structured around four strategic pillars:
- Historical and cultural imprint: Analyzes traditional fragrance ingredients for modern use.
- Sensorial influences: Researches cultural and botanical references to develop authentic scent profiles.
- Consumer insights: Surveys 10,000 people across various cities and generations, monitoring social media trends.
- Artificial intelligence: Translates insights into precise fragrance creation guidelines.
Arnaud Montet, VP of Global Human & Consumer Insights, stated that this large-scale research enables targeted fragrance development, reducing time and costs.
The initiative addresses key market challenges, such as evolving consumer preferences and the need for culturally authentic fragrances, enhancing IFF's ability to guide strategic decisions and create tailored scents for the Chinese market.
IFF announced significant changes to its Board of Directors, effective through 2025. Kevin O'Byrne, current board member and Centrica plc chair, will become Board Chair at the 2025 Annual Shareholder Meeting, succeeding Roger W. Ferguson, Jr. who will not seek reelection after 14 years of service.
Three new directors - Cynthia Jamison, Dr. Mehmood Khan, and Vincent Intrieri - will join effective January 1, 2025. Intrieri's appointment comes at Icahn Capital LP's request, replacing Gary Hu. Additionally, Christina Gold and John Davidson will not seek reelection in 2025, resulting in a ten-member board structure.
FAQ
What is the current stock price of International Flavors&Fragranc (IFF)?
What is the market cap of International Flavors&Fragranc (IFF)?
What does International Flavors & Fragrances Inc. (IFF) do?
What are the core business segments of IFF?
Where is IFF headquartered?
How many employees does IFF have?
What are some recent innovations by IFF?
What is the significance of the 'Timing is Everything' platform?
How does IFF support the food industry?
What role does IFF play in the health sector?
Where can I find more information about IFF's products and services?
What is IFF's approach to innovation?
